02833.4001LO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of:)	
(Div.	of U.S. Patent Appln. No. 09,674,674	:	
filed l	November 3, 2000))	
		:	Examiner: UNASSIGNED
BIRG	ER SÖRENSEN)	
		:	Group Art Unit: UNASSIGNED
Appli	cation No.: UNASSIGNED)	
		:	
Filed:	September 11, 2003)	
		:	
For:	HIV PEPTIDES, ANTIGENS,)	
	VACCINE COMPOSITIONS,	:	
	IMMUNOASSAY KIT AND A)	
	METHOD OF DETECTING	:	
	ANTIBODIES INDUCED BY HIV)	September 11, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449.

These documents were previously cited during the prosecution of parent Application No. 09/674,674. Accordingly, no copies are being provided herewith, in accordance with 37 CFR 1.98(d).

FEE OR STATEMENT

No fee or statement is required in connection with this Information Disclosure Statement, since it is being submitted prior to (1) the issuance of a first official action on the merits and (2) expiration of the three-month period following filing of the above-captioned application.

<u>REMARKS</u>

It is respectfully requested that the cited information be considered by the Examiner and that an annotated copy of the enclosed Form PTO-1449 be returned with the next official communication, indicating that such information has been considered.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our below-listed address.

Respectfully submitted

John W. Behringer

Registration No. 23,086

Attorney for Applicant

FITZPATRICK, CELLA, HARPER & SCINTO

30 Rockefeller Plaza

New York, New York 10112-3801

Facsimile No.: (212) 218-2200

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO.		APPLICATION NO.	4.4.1.		
			02833.4001LO		Div. of 09/674,674			
	IND TRADEMARK OFFICE ENCES CITED BY APPLIC	_	APPLICANT BIRGER SÖRENSEN					
(Use several sheets if necessary) Submitted: September 11, 2003			FILING DATE September 11, 2003			GROUP Unassigned		
			U.S. PATENT DOCUMENTS					
*EXAMINER DOCUMENT NUMBER DATE			NAME CLA		CLASS	SUBCLASS	FILING DATE SS IF APPROPRIATE	
		FCFC	REIGN PATENT DOCUMENTS			 		
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
	98/40744	9/1998	WIPO				Yes	
	96/27013	9/1996	WIPO				No	
	95/11255	4/1995	WIPO				No	
	94/28871	12/1994	WIPO				Yes	
	91/13360	9/1991	WIPO				Yes	
	0 356 007	2/1990	WIPO				Yes	
	01	THER DOCUMENT(S	S) (Including Author, Title, Date, P	ertinen	t Pages, Etc.)			
	Immunodeficie	ncy Virus Typ	no. 1, January 1999, loe 1 Genomes from Soe Recombination," p	ubty	pe C-Infected	., "Full-lengt Seroconvert	h Human ers in India,	
	Nature, vol. 354, December 1991, Rodney E. Phillips, "Human Immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition," pp. 453-459.							
	Human Retroviruses and Aids, Bette Korber et al., "Protein Alignment Summary Table (Gag)," II-A-1 to II-A-15, December 1997.							
	Virology, vol. 2, June 1994, Gabriel Zwart et al., "Antibody Resonses to HIV-1 Envelope and GAG Epitopes in HIV-1 Seroconverters with Rapid versus Slow Disease Progression," pp. 285-293.							
	Proceedings of the National Academy of Sciences, vol. 91, no. 23, November 8, 1994, Douglas F. Lake et al. "Autoantibodies to the α/β T-cell receptors in human immunodeficiency virus infection: Dysregulation and mimicry," pp. 10849-10853.							
	Clinical and Experimental Immunology, vol. 87, no. 1, January 1992, S.J.D. Bell et al., "Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1," pp. 37-45.							
EXAMINER			DATE CONSIDERED					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Submitted: September 11, 2003			ATTY DOCKET NO. 02833.4001LO		APPLICATION NO. Div. of 09/674,674			
			APPLICANT BIRGER SÖRENSEN					
			FILING DATE Sept mber 11, 2003			GROUP Unassigned		
			U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		FC	REIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
	0 270 114	12/1987	EPO				No	
	2 188 639	10/1987	United Kingdom				Yes	
	3711016	4/1987	Germany				No	
	0 230 222	7/1987	EPO				Yes	
	0	THER DOCUMENT(S	S) (Including Author, Title, Date, P	ertinen	t Pages, Etc.)			
	Nature, vol. 369, no. 6479, June 2, 1994, Paul M. Allen et al., "Promethean viruses," p. 355.							
	Nature, vol. 369, no. 6479, June 2, 1994, Paul Klenerman, et al., "Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants," pp. 403-407.							
	Nature, vol. 36	Nature, vol. 369, no. 6479, June 2, 1994, Antonio Bertoletti et al., "Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells," p. 407.						
		Immunology and Cell Biology, vol. 72, issue 6, December 1994, Gordon Ada, "Twenty years into the saga of MHC-restriction," pp. 447-454.						
	Specific Cytote Specificity of t	Journal of Immunology, vol. 147, no. 5, September 1, 1991, R.P. Johnson et al., "HIV-1 gag- Specific Cytotoxic T Lymphocytes Recognize Multiple Highly Conserved Epitopes" "Fine Specificity of the gag-Specific Response Defined by Using Unstimulated Peripheral Blood Mononuclear Cells and Cloned Effector Cells," pp. 1512-1521.						
	Science, vol. 2	Science, vol. 278, November 21, 1997, Eric S. Rosenberg et al. "Vigorous HIV-1-Specific CD4* T Cell Responses Associated with Control of Viremia," pp. 1447-1450.						
	Novelty Search Report issued by the Hungarian Patent Office on February 27, 2002 in counterpart Hungarian application (i.e., P0200265).							
EYAMINED			DATE CONSIDERED					

Form #61 DC Main_MAIN 143638v1

Sheet 2 of 2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.